Alnylam Pharmaceuticals (NASDAQ:ALNY) Posts Quarterly Earnings Results, Beats Estimates By $0.23 EPS

Alnylam Pharmaceuticals (NASDAQ:ALNY) released its earnings results on Thursday. The biopharmaceutical company reported ($0.52) earnings per share for the quarter, beating the consensus estimate of ($0.75) by $0.23, Briefing.com reports. The firm had revenue of $494.33 million during the quarter, compared to the consensus estimate of $428.01 million. During the same period in the prior year, the business posted ($1.40) earnings per share. Alnylam Pharmaceuticals’s quarterly revenue was up 54.8% compared to the same quarter last year.

Alnylam Pharmaceuticals Price Performance

Shares of Alnylam Pharmaceuticals stock traded up $2.02 during midday trading on Friday, reaching $152.33. The company had a trading volume of 452,157 shares, compared to its average volume of 763,489. The stock has a fifty day moving average price of $149.76 and a 200 day moving average price of $165.25. The firm has a market cap of $19.19 billion, a PE ratio of -42.22 and a beta of 0.41. Alnylam Pharmaceuticals has a fifty-two week low of $141.98 and a fifty-two week high of $218.88.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the company. William Blair reissued an “outperform” rating on shares of Alnylam Pharmaceuticals in a report on Monday, April 8th. Wolfe Research initiated coverage on Alnylam Pharmaceuticals in a report on Thursday, February 15th. They set a “peer perform” rating for the company. Cantor Fitzgerald restated a “neutral” rating and issued a $165.00 price target on shares of Alnylam Pharmaceuticals in a research report on Tuesday, February 20th. StockNews.com upgraded Alnylam Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Monday. Finally, Needham & Company LLC restated a “buy” rating and issued a $200.00 price target on shares of Alnylam Pharmaceuticals in a research report on Thursday. Seven investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $215.88.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.